AbCellera Biologics' stock experienced a significant 7.24% plunge in post-market trading on Monday. The biotechnology company had just released its first-quarter 2026 financial results.

Despite beating analyst expectations for both earnings per share and revenue, posting a loss of $0.14 per share versus an estimated loss of $0.20 and revenue of $8.3 million versus an estimated $5.86 million, investor reaction was sharply negative. The company reported a net loss of $43.2 million for the quarter, which narrowed from a loss of $45.6 million a year earlier but still represented substantial ongoing losses.

Market concerns appear to stem from the company's increased research and development expenses, which climbed to $46.7 million from $42.5 million a year ago, and a decrease in the number of downstream programs led by partners to 40 from 44 at the end of the previous quarter. While the company announced positive interim Phase 1 clinical data for its ABCL635 candidate showing robust target engagement and sustained effects, investors focused on the financial metrics and reduced partner pipeline.